Screener
Janux Therapeutics JANX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $10.27M— | $3.73M— | $0— | $10M+2,178% | $0-100% | ||
| $30.99M-10.6% | $26.81M+7.0% | $31.55M+51.6% | $34.63M+86.0% | $34.66M+133% | ||
| $10.96M+4.9% | $11.13M+13.1% | $10.85M+32.1% | $10.62M-39.9% | $10.45M+33.7% | ||
| $41.96M-7.0% | $37.95M+8.7% | $42.4M+46.1% | $45.25M+24.7% | $45.12M+98.6% | ||
| -$31.69M+29.8% | -$34.21M+2.0% | -$42.4M-46.1% | -$35.25M+1.6% | -$45.12M-226% | ||
| -308.7%— | -916.5%— | —— | -352.5%+7,812pp | —— | ||
| $9.72M-13.7% | $9.85M-13.5% | $10.46M+18.7% | $10.94M+40.5% | $11.26M+43.2% | ||
| -$21.97M+35.1% | -$24.36M-3.6% | -$31.95M-58.0% | -$24.31M+13.4% | -$33.86M-468% | ||
| -214%— | -652.6%— | —— | -243.1%+6,148pp | —— | ||
| -$0.35+36.4% | -$0.39-2.6% | -$0.51-45.7% | -$0.39+23.5% | -$0.55-400% | ||
| -$31.23M+29.9% | -$33.74M+1.8% | -$41.93M-47.1% | -$34.75M+1.6% | -$44.58M-235% | ||
| -304.1%— | -903.9%— | —— | -347.5%+7,701pp | —— | ||
| -$31.69M+29.8% | -$34.21M+2.0% | -$42.4M-46.1% | -$35.25M+1.6% | -$45.12M-226% |
FAQ
- What is Janux Therapeutics's revenue?
- Janux Therapeutics (JANX) generated $24.0M in revenue over the trailing twelve months, up 5367.0% year over year.
- Is Janux Therapeutics profitable?
- Janux Therapeutics is not currently profitable: it reported a net loss of $102.6M over the trailing twelve months, a -427.5% net margin.
- What is Janux Therapeutics's earnings per share?
- Janux Therapeutics's diluted EPS over the trailing twelve months is $-1.64.
- Where does Janux Therapeutics's income statement data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
